TB Archives – Page 29 of 47 – Treatment Action Group

2016 Report on TB Research Funding Trends

October 20, 2016
Chad Cipiti

Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to Treatment Action Group’s 2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time to Lose.

TAGline Fall 2016

October 17, 2016
Chad Cipiti

Health, Human Rights, and Social Justice: maximizing HIV, tuberculosis (TB), and viral hepatitis outcomes depends on the availability of state-of-the-art diagnostic and prognostic tools, engagement in expert and supportive care, and access to safe and effective drugs.

Petition to BRICS countries to triple funding for TB R&D

October 17, 2016
Chad Cipiti

Tuberculosis (TB) is the world’s deadliest infectious disease, and research into new ways to prevent, diagnose, and treat TB is urgently needed. BRICS countries—Brazil, Russia, India, China, and South Africa—are home to nearly half of all the world’s new TB cases and deaths, yet only provide 4 percent of funding for R&D to prevent them. In anticipation of the 6th Meeting of the BRICS Health Ministers, please join our call for BRICS countries to triple funding for TB research and development (R&D).

Countering the Contagion of Racism Through Resistance

October 14, 2016
Chad Cipiti

Upholding narratives of Black science and treatment activism, and community mobilization in HIV/AIDS and TB By Suraj Madoori In February 2016, startling data released by the Centers for Disease Control and Prevention (CDC) at the Conference of Retroviruses and Opportunistic…

Science and Solidarity

October 14, 2016
Chad Cipiti

Using human rights to strengthen TB research and access By Mike Frick Editor’s note: The following is based on the transcript of a plenary address delivered by the author at TB2016, a two-day TB conference held before the July International…

TAG Responds to the Release of the World Health Organization’s 2016 Global Tuberculosis Report

October 13, 2016
Chad Cipiti

TB is a preventable, curable disease, and the dismal lack of progress against reversing the TB epidemic is unacceptable. Last year, the World Health Organization (WHO) reported that TB had overtaken HIV as the world's leading cause of death from an infectious disease, and this year the WHO numbers show that the TB epidemic is larger than previously estimated

Open Letter: Hosting Union World Conferences on Lung Health in High-Burden Countries

August 24, 2016
Dorrit Walsh

Letter from individuals and organizations, including TAG, expressing concern over selection of host cities to host World Conferences on Lung Health.

Breathing Life into Flatlined U.S. Government Funding for Tuberculosis Research: FY 2017–2020 Allocations and Recommendations

June 12, 2016
Chad Cipiti

The End of TB Starts with Science: Eliminating tuberculosis (TB), the leading infectious killer in the world, won't happen without the critical leadership of the United States. Innovative policy making underpinned by catalyzing science has led to a dramatic reduction in the number of new TB cases each year in the country.

TAG Welcomes Delamanid’s Inclusion in the Stop TB Partnership’s Global Drug Facility

February 24, 2016
Chad Cipiti

Treatment Action Group (TAG) congratulates the Stop TB Partnership and Otsuka Pharmaceutical for arranging for the inclusion of delamanid, an important new medicine for treating some cases of multidrug-resistant tuberculosis (MDR-TB), in the Global Drug Facility (GDF). TB is the leading infectious cause of death globally, and new medicines to treat drug-resistant strains of TB are urgently needed.

TAG’s Response to the U.S. Action Plan for Combating Multidrug Resistant Tuberculosis

January 7, 2016
Chad Cipiti

Treatment Action Group (TAG) welcomes the release of the Obama Administration’s National Action Plan for Combating Multidrug-Resistant Tuberculosis. Strengthening the domestic and global and research efforts to address multidrug-resistant tuberculosis (MDR-TB) are critical to ending the suffering this preventable, curable disease needlessly causes. However, the targets set forth in this plan are not ambitious enough to effectively stop the spread of MDR-TB. The Administration and Congress must appropriate funding levels to ensure that the U.S. can effectively address MDR-TB.